Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exopolysaccharides: promising applications in bioremediation for waste removal.

Frontiers in microbiology·2026
Same author

Association Between Anthropometric Indices and Presence of Type 2 Diabetes Mellitus in Obesity.

Diabetes therapy : research, treatment and education of diabetes and related disorders·2026
Same author

Metacrinology.

JPMA. The Journal of the Pakistan Medical Association·2026
Same author

Efficacy and safety of semaglutide injection in Indian patients with type 2 diabetes mellitus inadequately controlled on metformin: a phase 3, randomized, active-controlled trial (SIZE-DM study).

Cardiovascular diabetology. Endocrinology reports·2026
Same author

Treatment Algorithm for Patients with Obesity in India: A Joint Consensus by Endocrine Society of India and Obesity Surgeons Society of India.

Obesity surgery·2026
Same author

Comparative Efficacy and Safety of Once-Weekly Semaglutide Formulations in Indian Adults With Obesity: A Phase III, Randomized Non-inferiority Active-Controlled Study (Size Plus Study).

Cureus·2026

Related Experiment Video

Updated: May 8, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Safety of statins.

Debasish Maji1, Shehla Shaikh, Dharmesh Solanki

  • 1Division of Cardiology, Department of Medicine, Vivekanand Institute of Medical Sciences, Kolkata, India.

Indian Journal of Endocrinology and Metabolism
|August 21, 2013
PubMed
Summary

Statins are safe and effective for reducing cardiovascular risk. Rare side effects like myopathy are manageable with awareness of drug interactions and individual statin properties.

Area of Science:

  • Pharmacology
  • Cardiology
  • Drug Safety

Background:

  • Statins are crucial for cardiovascular risk reduction.
  • Past concerns regarding statin-induced myopathy and rhabdomyolysis have been addressed.
  • Understanding pharmacokinetic properties has improved the safety profile of statins.

Purpose of the Study:

  • To review the underlying causes of statin-associated adverse effects.
  • To discuss the management of adverse effects in high-risk patient groups.
  • To highlight the safety and efficacy of statins, including potent agents like rosuvastatin.

Main Methods:

  • Review of existing literature on statin pharmacology and adverse effects.
  • Analysis of pharmacokinetic profiles and their relation to toxicity.
Keywords:
Myopathyrhabdomyolysissafety of statinsstatins

Related Experiment Videos

Last Updated: May 8, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

  • Examination of drug-drug interactions and management strategies.

    • Main Results:

    • Myopathy and rhabdomyolysis are rare, occurring at approximately 1/100,000 patient-years.
    • Statin-associated risks vary based on pharmacokinetic profiles and drug interactions.
    • High-dose rosuvastatin (80 mg/day) showed potential for proteinuria and hematuria, unlike lower doses.

    Conclusions:

    • Statins are generally safe and well-tolerated, with benefits outweighing risks.
    • Awareness of drug interactions and monitoring creatine kinase levels can minimize adverse effects.
    • Effective management strategies exist for statin-associated adverse events, particularly in high-risk individuals.